Integrating proteomics into precision oncology

Area of Science:

• Oncology
• Molecular Biology
• Proteomics

Background:

• Precision oncology utilizes DNA and RNA sequencing for targeted cancer treatment.
• Molecular tumor boards assess genetic alterations to guide therapy selection.
• There is a need for deeper patient characterization beyond genomic data.

Purpose of the Study:

• To assess the abundance and activity of 27 proteins in 134 cancer patients.
• To evaluate the utility of proteomic data in refining treatment recommendations within the MASTER program.
• To explore the integration of proteomic data with DNA and RNA sequencing for enhanced cancer therapy.

Main Methods:

• Proteomic and phosphoproteomic analysis of 27 targets in 134 tumor samples.
• Selection of targets based on relevant therapeutic baskets in the MASTER program.
• Integrative analysis of DNA, RNA, and protein data.

Main Results:

• Proteomic data supported DNA/RNA-based treatment recommendations in 10-57% of cases.
• Protein activities frequently suggested alternative therapeutic options.
• Protein activities correlated with patient clinical course and treatment failure.

Conclusions:

• Integrative analysis of multi-omics data (DNA, RNA, protein) can refine patient stratification in precision oncology.
• Proteomic profiling holds potential to increase the success rate of precision cancer therapy.
• Prospective validation studies are necessary to integrate proteomic analysis into routine clinical practice.